Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer

Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR) signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease. Even though abiraterone and enzalutamide represent breakthroughs in the treatment of mCRPC and have demonst...

Descripción completa

Detalles Bibliográficos
Autores principales: Boudadi, Karim, Antonarakis, Emmanuel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798019/
https://www.ncbi.nlm.nih.gov/pubmed/27013902
http://dx.doi.org/10.4137/CMO.Ss34534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798019/
https://www.ncbi.nlm.nih.gov/pubmed/27013902
http://dx.doi.org/10.4137/CMO.Ss34534

Ejemplares similares